In laboratories across Europe, researchers have just completed the most detailed map of immune cells ever made—a breakthrough that could reshape how doctors fight cancer. Scientists from VIB, VUB, and an international network of collaborators have created a comprehensive single-cell atlas of tumor-associated dendritic cells, integrating data from 14 mouse tumor models and 10 human cancer types to show, for the first time, exactly how these crucial immune defenders are organized and what happens to them when cancer takes hold.
Dendritic cells are the immune system's messengers—they sense danger and alert other immune cells to attack. But cancer has learned to silence them. Using single-cell RNA sequencing, the research team identified more than 30 distinct dendritic cell subsets and functional states lurking within tumors. Beyond the well-established populations like cDC1 and cDC2, they discovered emerging subsets such as DC3 and multiple intermediate or activated states. What struck the researchers most was how similar these populations were between mouse models and human patients, validating decades of preclinical research and opening new doors for testing therapies.
"This atlas gives us an unprecedented overview of dendritic cell diversity across cancers," says Prof. Damya Laoui from the VIB-VUB Center for Inflammation Research. "We can now clearly see how many different states these cells can adopt, and how similar they are between mouse models and patients."
The study reveals something unsettling: tumors don't just reshape dendritic cells locally—they reprogram them across the entire body. As tumors progress, dendritic cells acquire a stronger inflammatory profile, but the transformation extends far beyond the cancer site itself. Lymph nodes, the immune system's communication hubs, are also altered by the tumor's influence. This systemic effect surprised even the researchers. "We were surprised to see how broadly tumors influence the immune system," explains Aarushi Caro, a Ph.D. student and co-first author. "The reprogramming of dendritic cells extends beyond the tumor microenvironment, pointing to a systemic effect."
Understanding this landscape opens practical possibilities for treatment. By linking specific dendritic cell subsets to patient survival outcomes, the atlas highlights new opportunities for biomarker discovery—ways to identify which patients will respond to which treatments. More importantly, it reveals which dendritic cell states support anti-tumor immunity and which ones hinder it, knowledge that could enable the design of next-generation immunotherapies with unprecedented precision.
Rather than hoarding this data, the research team has made the entire dataset publicly available through an interactive platform, allowing researchers worldwide to explore the findings and build new discoveries on top of them. "Understanding which dendritic cell states support or hinder anti-tumor immunity opens new doors for therapy," says Dr. Daliya Kancheva, the other co-first author. "This resource will help guide the design of next-generation immunotherapies that more precisely target the immune system."
The work, published in Nature Communications, represents a fundamental shift in how scientists understand cancer's grip on immunity. By mapping the immune landscape with unprecedented detail and sharing that map freely, these researchers have given the global scientific community the tools to reimagine what's possible in cancer treatment.